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A B S T R A C T
Over the past few decades, there has been growing interest in understanding the molecular mechanisms of
cancer pathogenesis and progression, as it is still associated with high morbidity and mortality. Current man-
agement of large bone sarcomas typically includes the complex therapeutic approach of limb salvage or sacrifice
combined with pre- and postoperative multidrug chemotherapy and/or radiotherapy, and is still associated with
high recurrence rates. The development of cellular strategies against specific characteristics of tumour cells
appears to be promising, as they can target cancer cells selectively. Recently, Mesenchymal Stromal Cells (MSCs)
have been the subject of significant research in orthopaedic clinical practice through their use in regenerative
medicine. Further research has been directed at the use of MSCs for more personalized bone sarcoma treatments,
taking advantage of their wide range of potential biological functions, which can be augmented by using tissue
engineering approaches to promote healing of large defects. In this review, we explore the use of MSCs in bone
sarcoma treatment, by analyzing MSCs and tumour cell interactions, transduction of MSCs to target sarcoma, and
their clinical applications on humans concerning bone regeneration after bone sarcoma extraction.
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1. Introduction
Sarcomas are malignant neoplasms of mesenchymal tissue that are
classified as bone or soft tissue in origin [1]. Osteosarcomas and
chondrosarcomas are the most common malignant bone tumours, fol-
lowed by Ewing sarcomas [2]. Osteosarcomas and Ewing sarcomas
primarily affect children and adolescents, while chondrosarcoma in-
cidence increases with age [1]. Osteosarcoma and Ewing sarcoma re-
present 2.4% and 1.4% of childhood cancers, respectively [3]. Ewing
sarcoma is a small, round blue cell tumour that in children arises in
bone in 80% of the cases, whereas in adults, 75% of primary tumours
arise in soft tissue [4]. Osteosarcoma is characterized by the presence of
malignant osteoid and occurs primarily in the metaphysis of long tub-
ular bones of young patients with a median age of diagnosis of 15 to 19
years [4,5]. Following osteosarcoma, chondrosarcoma is the second
most frequent primary malignant bone tumour and is characterized by
the production of cartilage matrix [6]. The treatment of bone sarcoma is
challenging [7]. Intermediate and high-grade sarcomas are more fre-
quently treated with a combination of surgery, chemotherapy and/
or radiation therapy. Tumour resection depends on the cancer size and
grade, staging and sensitivity to neoadjuvant chemotherapy; it typically
requires wide tumour excision along with a margin of healthy tissue
around it. Multidrug chemotherapy and radiotherapy are adjuvant
treatments which reduce the risk of local and distant relapse, but with
major shortcomings including associated morbidity and poor targeting
efficiency to a tumour [8].
During the last 30 years, many new approaches to the treatment of
bone sarcomas have been developed; however, these have failed to
improve 5-year overall survival [8]. Targeting techniques aim to
achieve greater accumulation of antineoplastic agents in the tumour
whilst maintaining a non-toxic concentration in non-target organs and
tissues. Mesenchymal stromal cells (MSCs) may offer an advantage
through the delivery of antineoplastic agents or factors such as inter-
ferons, interleukins, TNF and antibodies selectively to tumour cells.
The emerging therapeutic role of SCs follows exponential progress
in understanding their natural behaviour and characteristics. Stem cells
interact with other cell types and are involved in tissue development,
regeneration, homeostasis, and evolution by natural selection [9]. Four
major categories of stem cells are currently encountered; embryonic,
fetal, adult and induced pluripotent SCs [10]. Although all types of SCs
can be used for medical research, adult SCs are usually utilized for
cellular therapies as they can be easily collected from patients, show
high multiplication capability in vitro and can migrate to target tissues
of the host [11]. On the other hand, the use of embryonic SCs face legal
and ethical restrictions in some countries and could be restricted as they
are available in limited quantities [10]. When it comes to SCs isolation
from fetus there are practical restrictions as it could harm the fetus and
is possible only during the early stages of life [11]. Mesenchymal
stromal cells are mainly obtained from adult tissues and are extensively
studied for their regenerative capacity through multipotent differ-
entiation [12] and antitumor activity [13]. Although MSCs are usually
isolated from the bone marrow, adipose tissue, and cord blood, they can
also be obtained from other tissues such as smooth, skeletal and cardiac
muscle, spleen, liver, pancreas, lung, testes, menstrual blood, perios-
teum, dermis, pericytes, trabecular bone, placenta, amniotic fluid,
dental pulp, hair follicle and peripheral blood [14]. Moreover, they
differentiate into mesodermal, endodermal and ectodermal lineage cells
[14]. Currently, two major categories are most widely studied among
MSCs; bone marrow MSCs (BMMSCs) and adipose tissue MSCs
(ADMSCs) [10]. Mesenchymal stromal cell populations are established
in niches; specialized microenvironments that play a central role in the
interaction between MSCs and adjacent cells to maintain tissue home-
ostasis through balancing self-renewal and differentiation [15]. In these
microenvironments, MSCs exhibit posterity, produce multiple hetero-
logical cell types and, through those multiple cell types, establish an
ECM specific for the niche [16]. The niche protects MSCs not only from
differentiation or apoptotic stimulus but also from overproduction that
may lead to carcinogenesis [17]. Cancer cells exploit similar mechan-
isms of the MSCs as the tumour sites share common functional features
with MSCs niches [18].
The mechanisms of tumour stroma generation and wound healing
appear to be contiguous. Mesenchymal stromal cells are attracted to the
site of the tumour by tumour-associated inflammatory signals [19,20].
Several studies have examined cell-cell and paracrine interactions be-
tween MSCs and tumour-cells, demonstrating a complicated relation-
ship between them, with MSCs potentially promoting or suspending
tumour progression even within the same cancer model [21]. In this
review, we explore the feasible therapeutic roles of MSCs in bone sar-
coma, analyzing MSCs and tumour interactions, transduction of MSCs
to target sarcoma, and clinical applications of MSCs in humans con-
cerning bone regeneration after bone sarcoma extraction.
2. Can we safely place MSCs near tumour cells?
2.1. MSCs and tumour cell interactions
Several factors can influence the interaction between MSCs and
cancer cells: the origin and pre-treatment of MSCs, the cancer type and
various in vitro and in vivo system-related factors (the ratio of MSCs
and cancer cells, simultaneous or sequential injection of MSCs and
cancer cells, local versus systemic MSC delivery or kinetics of carci-
nogenesis) [22].
In vivo and in vitro studies have confirmed that numerous factors
such as monocyte chemotactic protein-1 (MCP-1 or CCL2) in breast
cancer or stromal cell-derived factor-1 (SDF-1) in prostate, colorectal
and breast cancer that are produced by tumour and inflammatory cells
promote the homing and migration of MSCs into the tumour micro-
environment [23]. The homing and fate of mesenchymal stromal cells
have been related to cell to cell interactions that occur between MSCs
and tumour cells through cytokine/receptor pairs including stem cell
factor (SCF)/c-Kit; monocyte chemoattractant protein-1 (MCP-1)/
chemokine receptor 2 (CCR2); hepatocyte growth factor (HGF)/c-Met;
vascular endothelial growth factor/receptor (VEGF/VEGFR); stromal
cell-derived factor 1(SDF-1)/CXCR4; and high mobility group box-1
protein/ receptor for advanced glycation end-products (HMGB1/RACE)
[24–30]. Other inflammatory cytokines, growth and angiogenic factors,
also enhance migration of MSCs to the tumour site (Table 1).
Once MSCs are recruited by cancer cells, they enhance the pro-
duction of factors like TGF-β, VEGF, SDF-1, and CCL5 or microparticles
like exosomes that can either induce or inhibit tumour growth; owing to
this bimodal interaction, MSCs have been described as a ”double-edged
sword” [23]. The pro- or anti-tumorigenic effect of MSCs on tumour
progression depends mainly on the MSC source and the tumour model
used [31]. The pro-tumorigenic effect of MSCs includes four main
pathways: immunosuppression, tumour angiogenesis and epithelial-
mesenchymal transition (EMT)-mediated supplementation of tumour
[32](Fig. 1).
3. Pro-tumorigenic effect
3.1. MSC-mediated immunosuppression
The immunosuppression caused by MSCs promotes im-
munotolerance and tumour progression [33]. A prerequisite for the
immunomodulatory function of MSCs in the tumour microenvironment
is their activation by immune cells producing IFN-γ, TNF-a, IL-2a or IL-
1b [34–36]. Once MSCs are activated, they produce a number of mo-
lecules (namely TGF-b1, HGF, IDO, PGE2) that inhibit lymphocyte
proliferation and suppress the immune function of T lymphocytes,
dendritic cell maturation/differentiation, and NK and B-cell activation;
simultaneously, MSCs increase the production of regulatory T-cells
using a contact-dependent mechanism or by secreting IL-10 and TGF-b,
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[37–41]. Regarding specifically T cells, MSCs suppress their activity by
inhibiting their proliferation or, by causing apoptosis of already acti-
vated T lymphocytes [5].
3.2. Tumour angiogenesis
MSCs promote tumour angiogenesis either by their differentiation
into fibroblasts, pericytes, and myofibroblasts or by producing specific
growth factors [23]. Proangiogenic factors and chemokines expressed
by MSCs, including angiopoietin-1(Ang1), fibroblast growth factors-2
(FGF-2) and −7 (FGF-7), platelet-derived growth factor (PDGF),
stromal-derived factor-1 (SDF-1), IL-8 and vascular endothelial growth
factor (VEGF) act synergistically on endothelial cells to promote tumour
angiogenesis [42,43,44]. Other factors with potential pro-angiogenic
effect are angiogenin and CCL2 in lymphoma and hepatocyte growth
factor, cyclooxygenase, IGF-1 and transforming growth factor-a1 in
pancreatic carcinoma [45]. However, in some studies, MSCs suppressed
the production of the tumour angiogenic network by inhibiting the
growth of endothelial cell-derived capillaries through the production of
reactive oxygen species [5].
3.3. EMT-mediated supplementation of a tumour
Epithelial to mesenchymal transition (EMT) has a crucial role in
organogenesis, wound healing, tumour progression and metastasis.
MSCs facilitate and modulate EMT through the production of regulatory
molecules, namely TGF-b, E-cadherin and micro-RNA, resulting in more
invasive phenotype [46,47]. This theory was supported by the upre-
gulation of EMT-specific markers such as N-cadherin, vimentin, Twist
and Snail, and the decrease in E-cadherin when breast cancer cells and
MSCs were co-cultured [48].
3.4. Metastasis and Anti-apoptotic effects
Based on the type of tumour and MSC status, MSCs and their pro-
ducts can regulate the apoptosis of cancer cells [49–52]. MSC-induced
factors cause vascular formation and secretion of growth factors, pro-
moting invasion of cancer cells and the development of early tumour
metastasis [53]. The pro-metastatic effect of MSCs has been proven in
breast cancer (CCL5 and IL-17B), hepatocellular carcinoma (MMP2)
and osteosarcoma (CXCR4/VEGF axis) [23]. On the other hand, the
intravenous injection of UC-MSCs or ADMSCs in mice with mammary
tumours reduced the formation of lung metastases [50]. Thus, the role
of MSCs in the development of distant metastasis is controversial.
4. Antitumorigenic effect: the role of NF-κB, Akt and Wnt pathways
MSCs and cancer cells are thought to use similar signaling pathways
regulating self-renewal and differentiation, namely the Wnt/β-catenin,
Notch, Shh and BMP pathways [23,54]. Although the anti-tumorigenic
mechanisms of MSCs are not fully understood, it is presumed that they
are related to the downregulation of NF-κB, PI3K/Akt, and Wnt path-
ways [55]. Uneven activation of the Wnt/β-catenin pathway has led to
Table 1
Inflammatory cytokines, growth and angiogenic factors that enhance MSC migration to the tumour site.
Tumour released chemotactic factors Tumour model Stem Cell type Mechanism of action
Epidermal growth factor (EGF) Glioma [194] hBMMSCs Migration of SCs into the established human glioma although
they were injected at the opposite cerebral hemisphere
Pancreatic carcinoma [195] hBMMSCs Migration of SCs to tumour blood vessels due to a tumour
hypoxia-induced secretion of GFs including EGF
Melanoma, Mouse mammary
carcinoma [196]
BMPCs Migration of SCs to tumour site and recruitment to the
growing vasculature
Vascular endothelial growth factor-A (VEGF-A) Glioma [197] hMSCs Enhancement of the migration and invasion of SCs to the
tumour
Pancreatic carcinoma [195] hBMMSCs Migration of SCs from bone marrow to tumour blood vessels
mainly due to tumour hypoxia-induced secretion of VEGF
Platelet-derived growth factor (PDGF) Pancreatic carcinoma [195] hBMMSCs Migration of SCs to tumour blood vessels due to tumour
hypoxia-induced secretion of PDGF
Stromal-derived growth factor-1 (SDF-1) Osteosarcoma [92] hMSCs Enhancement of SCs migration to the tumour site and
promotion of growth and metastasis
Prostate tumour [198] ADSCs Migration of SCs to tumour site is possibly mediated by
homing factor SDF-1 (CXCL12)
Interleukin-8 (IL-8) Hec1a endometrial carcinoma [199] O-ASC Recruitment of SCs and possible tumour progression
CeC motif chemokine ligand 25 (CCL25) Multiple Myeloma (MM) [200] hBMMSCs Attraction of SCs to MM through the CCL25/CCR9 axis and
supportive role in MM cell growth
Hematoma-derived growth factor (HDGF) Breast carcinoma [201] hBMMSCs Promotion of SCs chemotaxis to the tumour site
Monocyte chemoattractant protein-1 (MCP-1) Primary & metastatic breast tumours
[202]
hMSCs In vivo and in vitro stimulation of SCs migration to tumour
site
Urokinase plasminogen activator (uPA)- Urokinase
plasminogen activator receptor (uPAR)
Malignant solid tumour (brain, lung,
prostate, breast) [203]
NSCs and MSCs Significantly greater migration of SCs to the tumour
expressing high levels of uPA and uPAR
Transforming growth factor beta-1 (TGF-β1) Breast cancer [204] hBMMSCs Attraction of SCs in the tumour site
C-X-C motif chemokine-1 (CXCL1) Hec1a endometrial carcinoma [199] O-ASC Recruitment of SCs to the tumour and possible tumour
progression
Neurotrophin-3 Malignant Glioma [205] MSC Combined with IL-8, TGF-beta1 overexpression, mediate
tropism of SCs to the tumour site
Tissue Inhibitor of Metalloproteinase-1 (TIMP-1) Glioma [206] hNSC Regulation of CD63 and β1 integrin-mediated signalling and
enhancement of SCs adhesion and migration
Factors:
GF: growth factor, EGF: Epidermal growth factor, VEGF-A: Vascular endothelial growth factor-A, PDGF: Platelet-derived growth factor,SDF-1: Stromal-derived
growth factor-1, IL-8: Interleukin-8, CCL25: CeC motif chemokine ligand 25, HDGF: Hematoma-derived growth factor, MCP-1: Monocyte chemoattractant protein-
1,uPA: Urokinase plasminogen activator,uPAR: Urokinase plasminogen activator receptor,TGF-β1: Transforming growth factor beta-1,CXCL1: C-X-C motif che-
mokine-1, Neurotrophin-3, TIMP-1: Tissue Inhibitor of Metalloproteinase-1.
Cell types:
hBMMSCs: Human Bone Marrow-derived Mesenchymal Stromal Cells, hMSCs: Human Mesenchymal Stromal Cells, ADSC: Adipose Tissue-derived Stem Cells, O-
ASC: Omental Adipose Tissue Stromal Cells, NSCs: Neural Stem Cells, MSCs: Mesenchymal Stromal Cells, MSC: Bone Marrow Stromal Cells, hNSC: Human Neural
Stem Cells, MSC: Bone Marrow Stromal Cells, BMPCs: Bone Marrow-derived Perivascular Cells.
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the development of a variety of human tumours [56,57]. Human um-
bilical cord-derived MSCs (hUC-MSCs) co-cultured with glioma cells
downregulate β-catenin expression in glioma cell lines and increase the
levels of secreted DKK1 which is an inhibitor of the Wnt pathway [58].
The anti-tumorigenic and pro-apoptotic effect of MSCs results from the
suppression of the phosphoinositide 3-kinase/protein kinase B (PI3K/
Akt) signaling pathway in some cancer types [59]. However, many
factors secreted by MSCs activate the PI3K/Akt pathway in other cancer
types and this effect may depend on the metabolic or genetic profile of
cancer cells [60]. Existing data from pre-clinical studies regarding the
pro-apoptotic effect of MSCs on cancer cells through the down-
regulation of PI3K/Akt pathway support this antitumor potential in
hepatocellular carcinoma, glioma cells, Kaposi's sarcoma, and prostate
and breast cancer [61–65]. Other possible mechanisms that contribute
to the anti-tumour potential of MSCs include apoptosis caused by up-
regulation of TRAIL, G1 arrest, and expression of tumour suppressor
genes [23] (Fig. 2).
4.1. Safety of use of MSCs in proximity to a tumour
The unique characteristics of MSCs (self-renewal, differentiation,
and tropism to the tumour site) raised expectations of possible ther-
apeutic applications in cancer patients. Major safety issues and
knowledge gaps, however, remain to be explored [66].
The role of MSCs in different cancer types is ambiguous. In vivo
animal studies of murine melanoma and renal murine adenocarcinoma
(Renca kidney cancer cells) showed that co-implantation of MSCs in-
creased tumour size possibly because of MSC-mediated
Fig. 1. MSC pro-tumorigenic effect main pathways.
Fig. 2. MSC anti-tumorigenic and pro-apoptotic effect.
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immunosuppression [67,68]. The production of trophic factors from
MSCs including VEGF, chemokine CCL5 and IL6 (activation STAT-3)
has been connected with tumour growth and metastasis in Burkitt's
lymphoma, breast cancer, colonic cancer and chronic myeloid leu-
kaemia [69–73]. Rowan et al. investigated the safety of human adipose
tissue-derived stromal cells (ADSC) included in fat grafts that were used
for reconstruction after surgical resection of a breast tumour. The ap-
plication of human ADSCs in proximity to breast cancer raised concerns
as it was associated with an increase in the migration and metastasis of
cancer cells [74]. In an animal study, Zheng et al. scrutinized whether
the proximity of breast tumour cells (4T1) and bone marrow-derived
mesenchymal stromal cells (BMMSCs) could affect tumour growth. In-
terestingly, they found that the co-injection of 4T1 cells and BMMSCs
accelerated cancer cell proliferation, whereas simultaneous distant in-
jection had the opposite results. When MSCs were injected distantly
from cancer cells, they had immunoregulatory action by decreasing the
accumulation of myeloid-derived suppressor cells and regulatory T cells
at the tumour site [75]. Another mechanism that could increase the
aggressiveness of a tumour is the potential differentiation of MSCs to
tumour associated fibroblasts that are capable of increasing neovascu-
larization within the tumour stroma and the metastatic rate [76,77].
4.2. MSCs and bone sarcoma interactions
One human and several animal studies have investigated the safety
of using MSCs in proximity to bone sarcomas by exploring MSCs and
tumour cell interactions [78–93]. Aanstoos et al. evaluated the safety of
application of MSCs in mice with osteosarcoma. They used three
groups: mice receiving MSCs intravenously or at the surgical site fol-
lowing tumour resection and mice receiving no MSCs; and they eval-
uated both the development and progression of pulmonary metastasis
and local recurrence. Mice that received MSCs intravenously developed
the first detectable metastases significantly earlier (2.93±1.90 days)
than those that received local injection of MSCs (6.94±6.78 days) and
those that received no MSCs (5.93±4.55 days). The recurrence rate
and the size of the recurrent tumours, however, were not affected sig-
nificantly by delivery of the MSCs at the surgical site or intravenously
[94].
The co-implantation of rat BMMSCs and COS1NR osteosarcoma
cells resulted in the acceleration of non-metastatic cancer settlement
and proliferation in a study by Tsukamoto et al. All animals in which
MSCs and osteosarcoma cells were co-implanted developed tumour by
week 4, compared to those that received only osteosarcoma cells and
developed tumour by week 6. However, there was no significant sta-
tistical difference in tumour size after six weeks and in the number of
metastases between the two groups. On the other hand, intravenous
BMMSC injection led to stabilization of the initial tumour size, without
altering its histological appearance, and significant enhancement of
metastatic lung nodules (17.33±8.39 vs. 2.0 ± 2.0, p=0.03). The
overexpression of the CXCL12/CXCR7 axis was probably involved in
osteosarcoma cell-MSCs interaction that led to an increase in pul-
monary metastases and tumour progression. Moreover, the elevation of
the basement membrane degrading enzymes, MMP-2 and MMP-9 in
MSCs, was connected with increased tumour metastasis [95]. The pro-
tumorigenic effect of locally administrated MSCs could be correlated
with the number of MSCs applied. Lee et al. showed in an animal study
that local administration of ADMSCs in low proportions suppress tu-
mour growth, whereas higher proportions show a tumour-promoting
effect [88]. In vivo mice studies also indicated that MSCs could promote
CXCR-4-mediated osteosarcoma proliferation and pulmonary metas-
tasis through the production of VEGF by MSCs [89]. In vitro co-culture
of osteosarcoma cells and BMMSCs showed that SCF-1 secreted from
BMMSCs promoted the proliferation and invasion of osteosarcoma cells.
In contrast to BMMSCs, osteosarcoma cells expressed higher levels of
CXCR4, indicating that the SDF-1/CXCR4 axis plays a pivotal role in
osteosarcoma cell proliferation [96]. Another in vivo mice model
indicated that SDF-1 could also be secreted from Saos-2 cells in the
conditioned medium and enhance the migration of hMSCs to the tu-
mour site, where osteosarcoma cell growth and pulmonary metastasis
are promoted by the secretion of CCL5 from exogenous hMSCs [92].
Moreover, pre-clinical data showed that BMMSCs could promote os-
teosarcoma growth through PI3K/Akt and Ras/Erk intracellular cas-
cades, and enhance metastasis through CXCR4 signaling [91].
Avril et al. investigated the interaction of human osteosarcoma cells
with human adipose tissue-derived stromal cells (ADSCs), MSCs ob-
tained from bone marrow, and pre-osteoclasts when co-injected in
immunodeficient mice. Adipose tissue-derived stromal cells constitute a
population of MSC-like cells that are used in plastic and reconstructive
surgery. They found that ADSCs and MSCs increased tumour size while
pre-osteoclasts did not; none of them, however, increased metastasis.
The cell cycle of proliferating osteosarcoma cells was accelerated by
factors secreted by MSCs, in contrast to the quiescent state of dormant
tumour cells that remain stable. They concluded that ADSCs/MSCs
could be used for reconstructive surgery after osteosarcoma resection;
however, they may not be good candidates for targeted cell therapy as
they may enhance tumour cell proliferation [97]. Soluble factors se-
creted from adipose tissue, such as IL-6 and leptin, induced the acti-
vation of osteosarcoma cell cycles from G1 to mitosis phases and thus
increased the local growth of a tumour. However, they do not promote
lung metastasis and osteolysis [80].
Interleukin-6 (IL-6) seems to play a pivotal role in the bidirectional
proliferation of human MSCs (hMSCs) with Saos-2 both in vitro and
nude mice models. Interestingly, IL-6 produced from the conditioned
medium of Saos-2 could inhibit osteogenic differentiation of hMSCs
[98]. A probable explanation for IL-6 mediated promotion of osteo-
sarcomas is through the STAT3 signalling pathway. IL-6 secreted from
MSCs activates STAT-3 in adjacent osteosarcoma cells in a concentra-
tion-dependent manner, promotes their proliferation, protects them
from chemotherapeutic drugs such as cisplatin and enhances their mi-
gration and invasion properties [82]. Tu et al. also demonstrated that
the co-implantation of Saos-2 and MSCs activated STAT-3 by IL-6 and
increased the expression of multidrug resistance protein (MRP) and P-
glycoprotein that induced chemoresistance in doxorubicin and cisplatin
in mice osteosarcoma samples [99]. The ADMSCs-mediated activation
of the STAT-3 pathway in osteosarcoma increased MMP2/9 and de-
creased E-cadherin expression, promoting tumour progression [83].
In assessing the safety of the use of MSCs for bone healing Hernigou
et al. retrospectively evaluated 92 patients with chondrosarcoma (31/
92), osteosarcoma (35/92), Ewing's sarcoma (28 /92) and other bone
tumours (8/92), who received autologous BMMSCs following tumour
resection to enhance the healing of the host-to-allograft bone junction.
They evaluated the risk of local recurrence after surgical tumour re-
section at a mean follow-up of 15.4 years. They found no increase in the
risk of local recurrence for all cancer types [100]. However, as referred
to earlier, there were safety concerns about human adipose-tissue
stromal cells (ASC) included in fat grafts that increased migration and
metastases of breast tumour and osteosarcoma animal models [74,101].
Autologous fat grafts used in reconstructive surgery have also been
related to late local recurrence, 13 years following the onset of osteo-
sarcoma in a female human patient. Successive pre-clinical models
showed that MSCs/stromal cells included in the fatty tissue interact
with osteosarcoma cells and induce their proliferation [101].
Studies support the hypotheses that the use of MSCs could accel-
erate pulmonary metastases after resection of the primary osteo-
sarcoma, promote the proliferation of osteosarcoma cells at the tumour
site and increase chemoresistance (Table 2). However, current knowl-
edge refers mainly to in vitro and in vivo animal models and has not yet
been translated to the clinical setting. It is not clear whether there is a
biological reason suggesting that intravenously administrated MSCs
have a predilection for locating within the lungs through their inter-
action with lung metastases or they are likely to be entrapped in the
lungs as they are a first pass tissue. Intracardiac or arterial injection of
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MSCs in future studies could help us understand the exact mechanism of
presumptive acceleration of pulmonary metastases.
5. Pre-activation and use of transduced MSCs to induce sarcoma
cell apoptosis
5.1. Induction of cancer cell death using transduced MSCs
The use of transduced MSCs to express specific anti-cancer proteins
selectively to the tumour site offers a promising therapeutic approach.
Several proteins, molecules or drug systems have been implicated.
5.1.1. Interferons
Human MSCs genetically engineered to produce interferons have
been used to deliver these proteins locally in several cancer models,
such gliomas, metastatic breast, melanoma, endometrial, ovarian, he-
patocellular, bronchioloalveolar and prostate models. MSCs expressing
IFN-β can reduce tumour size, induce apoptosis and increase survival in
the aforementioned cancer types [55,102,103,104,105,106,107,108].
Similarly, IFN-α expressing MSCs were effective in increasing cancer
cell apoptosis and suppressing angiogenesis in metastatic melanoma
and hepatocellular carcinoma models [109]. IFN-γ-expressing MSCs
also inhibited leukemic and lung carcinoma cell proliferation in vitro
[35,110,111]. However, when IFN-γ-human BMMSCs were tested
against H460 cells in an animal model, their pro-tumorigenic effect was
superior through the promotion of vascularization [112].
5.1.2. Interleukins
Adenovirus-transduced MSCs that expressed interleukin-12 (IL-12),
reduced metastases from subcutaneous tumours [113]. A tumour sup-
pressive effect of IL-12 secreted from genetically modified MSCs was
also confirmed in a breast carcinoma model [114,115]. MSCs developed
to deliver IL-2 and IL-21, when injected into murine gliomas and epi-
thelial ovarian cancer respectively, reduced tumour growth and im-
proved survival [116]. Interestingly, transduced BMMSCs expressing IL-
18 and IFN-β promoted apoptosis of cancer cells in an intracranial
glioma model [117]. Chemokine CX3CL1 intravenously delivered from
transduced MSCs to colon cancer, and melanoma reduced the number
of lung metastases [118].
5.1.3. Viruses
MSCs have already been used as vectors of oncolytic adenoviruses in
several in vitro and in vivo studies and improved survival in murine
ovarian, breast and lung tumour models. Viral replication and invasion
to the surrounding tumour tissue induced apoptosis of cancer cells [55].
Komarova et al. studied the impact of MSCs infected by genetically
modified coxsackie and adenoviruses against animal ovarian cancer.
They showed that MSCs mediated infection of cancer cells had better
Table 2
In vitro, in vivo and clinical data on safety of stem cells in proximity to bone sarcomas.
Author/ Year Model Used Methods/ Results Conclusion
Hernigou P/ 2014
[100]
Retrospective cohort
study of humans
• 92 humans suffering from chondrosarcoma (31 patients),
osteosarcoma (35 patients), Ewing's sarcoma (28 patients) and other
bone tumors (8 patients)
• A longer follow-up period is required as some solid
malignant tumors are developed after a 20–40- year
latent period
• Risk of local tumor recurrence after surgical resection and
autologous BMMSCs for bone defect reconstruction during 15.4 years
mean follow-up is not increased
• Local recurrence when MSCs are administrated beyond
the two-year period after bone resection should be
investigated
Aanstoos ME/
2016 [94]
In vivo animal study • Adipose tissue-derived MSCs (ADMSCs) were applied in mice with
osteosarcoma
• Intravenous delivery of MSCs could promote
pulmonary micrometastasis
• Study included three groups; mice receiving intravenous MSCs, mice
receiving MSCs at the surgical site following resection and mice
receiving no MSCs
• Local application at the surgical site appear to be safe
in murine model
• The group of intravenous administrated MSCs presented metastases
earlier than the other two groups
• Further investigation is needed before using MSCs in
human with osteosarcoma
Avril P/ 2016
[97]
In vivo animal study • Human MSCs, ADSCs and pre-osteoclasts were co-injected with
human MNNG-HOS osteosarcoma cells in mice
• ADSCs/ MSCs appear not to increase the risk of local
recurrence when used for reconstructive surgery after
bone tumor resection
• MSCs and ADSCs increase MNNG-HOS osteosarcoma growth with-
out exacerbation of osteolytic lesions and lung metastases
• ADSCs/ MSCs when used for tumor-targeted cell
therapy can enhance tumor progression
• ADSCs increase tumor growth in a dose-dependent manner
• ADSCs and MSCs produce factors that may accelerate the cell cycle of
proliferating osteosarcoma cells
Bian Z-Y/ 2010
[98]
In vivo animal study • Saos-2 with or without co-injection of hMSCs were injected into the
proximal tibia of nude mice
• There is a positive feedback loop of IL-6 in interaction
between hMSCs and Saos-2
• exogenous hMSCs target the osteosarcoma site and promote its
growth and pulmonary metastases
• ALP levels were increased in response to co-injection of Saos-2 and
hMSCs
• hMSCs and Saos-2 could enhance their own proliferation through IL-
6 autocrine
Perrot P/ 2010
[101]
In vivo animal study • 21 mice were divided in 3 groups: the control Saos-2 group,
Saos-2+ fat group and Saos-2+ cannula group
• Clinicians must be aware of the possible long term local
relapse of osteosarcoma after autologous fat graft
• Human adipose tissue-delivered stromal cells (ADSC) included in fat
grafts can induce osteosarcoma cells proliferation
Tu B/ 2016 [99] In vitro and in vivo
animal study
• MSCs protect osteosarcoma cells from drug-induced apoptosis • STAT-3 pathway should be further studied in order to
overcome environment-induced chemoresistance
• Co-implantation of Saos-2 and MSCs leads to activation of STAT3 by
IL-6 and increase not only the expression of multidrug resistance
protein (MRP), but also P-glycoprotein
Factors:
ALP: alkaline phosphatase, MRP: multidrug resistance protein.
Cell types:
BMMSCs: Bone Marrow-derived Mesenchymal Stromal Cells, MSCs: Mesenchymal Stromal Cells, ADMSCs: Adipose tissue-derived MSCs, ADSC: Adipose Tissue-
derived Stem Cells, MNNG-HOS: human osteosarcoma cell line, Saos-2: osteosarcoma cell line.
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results in decreasing tumour size and increasing of survival rate com-
pared with the directly injected adenovirus [119].
5.1.4. TNF
Cancer cell apoptosis mediated by the tumour necrosis factor (TNF)
cytokine superfamily was first proposed almost 30 years ago. TNF-α
was the first assessed cytokine that proved to be ineffective in triggering
cancer cell apoptosis and also had severe adverse events [120]. Atten-
tion has now turned to other members of the TNF superfamily.
5.1.5. TRAIL
Tumour necrosis factor related apoptosis-inducing ligand (TRAIL)
[121] is a type 2 transmembrane ligand that causes the death of tumour
cells through the extrinsic apoptosis pathway and activation of caspase-
8 [122]. TRAIL could be an ideal antitumor candidate for specific tu-
mour types, as in most cases it causes the selective death of malignant
cells [123,124]. However, TRAIL has a short pharmacokinetic half-life
when administrated intravenously and this limits its usefulness when
given systemically [124]. Genetically modified MSCs expressing TRAIL
could offer targeted and prolonged delivery of the ligand [125,122].
Viral vectors have already been used to develop transduced MSCs that
were studied against lung, renal, pancreatic, cervical, breast and colon
cancer, malignant pleural mesothelioma, neuroblastoma, rhabdomyo-
sarcoma, squamous cell carcinoma, metastatic malignant fibrous his-
tiocytoma and multiple myeloma [126]. Recently, in vivo and in vitro
studies indicated that MSCs expressing TRAIL caused apoptosis more
effectively than recombinant human TRAIL (rh-TRAIL), and overcame
TRAIL resistance of some cancer types [126]. Moreover, recent data
support that the pancreatic cancer sensitivity to MSC-delivered TRAIL
could be restored by combined administration of MSCs expressing
TRAIL and a paclitaxel (PTX)-based chemotherapy [127].
5.1.6. Antibodies (Abs)
Antibodies that are produced in vitro and then administrated into
the systemic circulation have a short-half life and cannot approach the
tumour site. To overcome this difficulty, Compte et al. developed ge-
netically engineered hMSCs to secrete a bispecific diabody, resulting in
a powerful systemic antitumoral effect even though the diabodies were
produced distantly [125]. In a recent animal study, human umbilical
cord-derived MSCs were genetically modified to produce a bispecific Ab
(Tandab CD3/CD19) against B cell lymphoma and inhibited cancer cell
proliferation [128].
5.1.7. Enzyme/prodrug systems
Ghaedi et al. used lentivirus-transduced hMSCs to deliver a1-anti-
trypsin (AAT) to solid tumours and caused cytotoxicity against umbi-
lical cord vein endothelial cells [129]. The gene-directed enzyme-pro-
ducing therapy uses MSCs for targeted chemotherapy through a
prodrug conversion approach [130]. Uchibori et al. combined MSCs
that produced herpes simplex virus-thymidine kinase retroviral vectors
with the prodrug ganciclovir leading to glioma cell death both in vitro
and in vivo [131].
Similarly, extensively studied enzyme/prodrug systems included
cytosine deaminase (CD) combined with 5-fluorocytosine (5-FC) and
carboxylesterase with the prodrug CPT-11 (irinotecan) for the treat-
ment of colon cancer, osteosarcoma [132] or glioblastoma and brain
stem glioma, respectively [133]. Mesenchymal stem cells engineered to
produce the CD enzyme, which converts the substrate 5-FC to the
highly toxic 5-fluorouracil, have been used in melanoma and colon
cancer. The tumour size was reduced; however, they also caused toxi-
city to healthy tissues [134,135].
5.1.8. Other factors
Pigment epithelium-derived factor (PEDF) and NK4 are agents that
have been studied against lung carcinoma and gastric cancer, respec-
tively. Transfection of MSCs to secrete these agents was effective inTa
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cancer cell apoptosis and suppression of metastases [136–139].
5.2. Use of transduced MSCs to induce bone sarcoma cell apoptosis
The ability of MSCs to migrate to the primary tumour site raised the
possibility of using them like drug or gene carriers. Transduced MSCs
producing novel anti-cancer proteins molecules or drug systems such
TRAIL, osteoprotegerin, cytosine deaminase/5-fluorocytosine (CD/5-
FC) and IL-2 selectively to the tumour site, have also been studied ex-
tensively in bone sarcoma models (Table 3).
5.2.1. TRAIL
Transduced MSCs expressing TRAIL are promising for several cancer
types; however, their efficacy against bone sarcomas remains con-
troversial [126]. As noted previously, TRAIL delivered by ADMSCs had
a greater anti-tumorigenic effect on osteosarcoma than rh-TRAIL alone.
Despite the high levels of OPG, TRAIL cell delivery could be effective
against SAOS-2 cells since MSCs offer a longer half-life and more stable
TRAIL delivery and secretion of synergizing factors [140]. Transduced
MSCs expressing TRAIL have anticancer activity in sarcoma models
causing extensive apoptosis of sarcoma and potent antiangiogenic
functions both in vitro and in vivo. This pro-apoptotic effect is thought
to be controlled by the activation of caspase-8 [140]. Grisendi et al. also
demonstrated the effectiveness of the approach in a metastatic lung
model of Ewing's sarcoma, as ADMSCs were capable of migrating into
the lung and persisting after last inoculation [140].
Several pre-clinical studies have proved the effectiveness of TRAIL
against cancer cells, however, some Ewing sarcoma cell lines were
TRAIL-resistant in vitro [141–143]. To overcome this resistance, Guiho
et al., developed transduced ADMSCs producing TRAIL that induced
cell death even in rh-TRAIL-resistant Ewing sarcoma cell lines. Direct
cell-to-cell contact of Ewing sarcoma cells and the transduced ADMSC
was necessary to cause cancer cell apoptosis through the clustering of a
high level of death receptors. Two different orthotopic in vivo Ewing
sarcoma models in mice also confirmed the efficiency of ADMSC ex-
pressing TRAIL [144]. In a more recent study, of a para-tibial orthotopic
osteosarcoma mouse model using rh-TRAIL resistant K-HOS cells, the
delivery of ADMSCs expressing TRAIL into the tumour site did not slow
down tumour progression [145]. This was despite promising in vitro
data demonstrating that MSC-TRAIL could induce significant K-HOS
cell apoptosis in direct co-culture. Possible reasons given for the in vivo
findings were the non-optimal target: effector ratio and lack of physical
contact between the SCs and cancer cells. Furthermore, two of the MSC
inoculated treatment groups demonstrated accelerated tumour pro-
gression [145].
5.2.2. Osteoprotegerin (OPG)
Osteoprotegerin is a soluble glycoprotein and a member of the TNF
receptor superfamily. It has a crucial role in bone metabolism as a
decoy receptor for RANKL in the RANK/RANKL/OPG axis, inhibiting
osteoclastogenesis and bone resorption [146]. Osteoprotegerin impedes
osteosarcoma progression by inhibiting RANKL whose secretion is en-
hanced in the bone tumour microenvironment. However, OPG was in-
effective outside bone as it could not prevent pulmonary metastasis
[147]. Qiao et al. developed MSCs transfected with adenoviruses car-
rying the OPG gene to prolong OPG's half-life and enhance its delivery
directly to a tumour site. When administered to mice with osteosarcoma
through the tail vein, the engineered MSCs were capable of migrating to
the osteosarcoma site, producing OPG locally, reducing tumour growth
and inhibiting bone destruction by osteosarcoma. The tumour volume
at day 30 in mice that received MSCs-OPG was reduced by 65.2%
compared to those administrated with PBS solution. Additionally,
transduced MSCs were detected in treated mice, but with no increase in
serum OPG levels was seen even 30 days after systematic administra-
tion, demonstrating fewer side effects of systemic administration [148].
5.2.3. CD/5-FC
Cytosine deaminase (CD) is a lethal gene which encodes an enzyme
catalyzing the conversion of cytosine into uracil and the non-toxic
prodrug 5-fluorocytosine (5-FC) into the cytotoxic agent 5-FU which
has anti-tumour activity. The CD/5-FC system is very effective against
human cancers by inhibiting DNA synthesis and promoting apoptosis of
tumour cells [149].
MSCs expressing the CD/5-FC product (CD/5-FC MSCs) to promote
cancer cell apoptosis is a novel but insufficiently studied model. They
have been already evaluated in colorectal cancer and lung metastases
with promising results [150,151]. Nguyen Thai et al. assessed the ef-
ficacy of CD/5-FC MSCs against human osteosarcoma cells in vitro and
in vivo. They administrated MSCs bearing the CD gene combined with
the nontoxic 5-FC prodrug. Interestingly, transduced MSCs were more
capable of migrating towards osteosarcoma cells than native MSCs. The
tumour volume increased at days 2–3 following the administration of
CD MSCs, however, when the 5-FC prodrug was administered the tu-
mour volume was gradually decreased from the fifth day. CD MSCs that
were taken together with the 5-FC prodrug showed significant cyto-
toxicity against osteosarcoma cells in an animal model [132].
5.2.4. IL-12
The beneficial activity of IL-12 has been shown in several cancer
models; however, initial enthusiasm faded due to severe toxicity with
systemic administration. To overcome this, local gene delivery strate-
gies have been used. Aerosol therapy including a polycationic IL-12-
gene carrier was effective in reducing both the number of lung metas-
tases and the nodule size in mice with established osteosarcoma lung
metastases [152]. In addition, IL-12 increased Fas expression in osteo-
sarcoma and Ewing's sarcoma cells through the enhancement of Fas
promoter activity, causing cancer cell apoptosis [153,154]. The local
gene delivery of IL-12 using adenoviral vectors may be effective for
Ewing's sarcoma but not in patients with distant tumour metastases
[155]. The anti-tumoural effect of IL-12 to osteosarcoma and Ewing's
sarcoma and the ability of MSCs to migrate to the tumour site can be
combined to deliver IL-12 locally to tumours. Murine MSCs infected
with an adenoviral vector carrying the IL-12 gene injected into mice
bearing Ewing's sarcoma were localized and produced IL-12 selectively
in the tumour. Moreover, MSCs were also found in the lungs, spleen,
and liver without harming these organs. p35 and p40 subunits of IL-12
were expressed in the tumour site, inhibiting tumour growth [156].
6. MSCs as delivery vehicles of anti-tumor nanoparticles to trigger
bone sarcoma cell death
The tropism of MSCs to cancer tissue suggests their use as vehicles
for local delivery of antineoplastic agents. Mesenchymal stem cells can
pass through endothelium and following blood flow migrate to the
tumour site increasing targeting efficiency and reducing normal tissue
toxicity [157]. Moreover, human MSCs can use an active efflux pump
system to gain resistance to anticancer drugs they transfer [158,159].
However, according to a study published by Belmar-Lopez et al., the
MSC lineage to be used in a cell therapy should be carefully chosen as
its safety and efficacy could vary between tumour types [160]. More-
over, antineoplastic agents that are used in MSC delivery systems would
possibly destroy MSCs and lead to failure of this technique. To over-
come this obstacle, Duchi et al. developed MSCs loaded with core-shell
PMMA nanoparticles (FNPs) and meso‑tetrakis (4-sulfonataphenyl)
porphyrin (TPPS) which is a photosensitizer. When these MSCs were co-
cultured with human osteosarcoma cell line U2OS-RFP-TUBA1B in vitro
and upon light irradiation, they induced controlled osteosarcoma cell
death through the generation of reactive oxygen species [161].
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7. Clinical evidence of MSC use for bone defect regeneration after
osteosarcoma resection
The biological filling of a bone defect [BD] after the surgical re-
section of a tumour is often difficult. Physiological healing mechanisms
cannot cope with defects greater than 2 cm(178). The dominant role of
MSCs in bone regeneration and fracture healing [162,163] combined
with their antitumor properties raised the possibility of a role in filling
the BD after bone sarcoma therapy [164].
Contemporary engineering and regenerative medicine techniques
[165] using molecular [166–168] and mechanical “guidance”
[169–171] can differentiate ADMSCs into various tissue types. Previous
animal studies (157,155) demonstrated the regenerative ability of SCs
that were applied either intravenously or topically, loaded on a dif-
ferent type of scaffolds [172,173,100]. Although MSCs have been used
in humans to promote bone formation, concerning bone sarcoma, there
are obvious limitations in their use [101,174,175]. Following the first
application of MSCs by Herzog in 1951, many steps forward have been
accomplished to find better, more effective and less harmful techniques
[176] but still, we are far from fully understanding the complex in-
tracellular mechanisms, or safe use in clinical practice and from broad
application of MSCs at BDs following osteosarcoma treatment [177]. To
the best of our knowledge, three reported techniques use MSCs to fill
musculoskeletal BDs after bone tumour extraction.
7.1. Direct local application of MSCs
Hernigou et al. as mentioned earlier, evaluated the local application
of autologous BMMSCs to enhance the healing of the host-to-allograft
bone junction following bone tumour resection in 92 patients with
chondrosarcoma, osteosarcoma, Ewing's sarcoma or other tumours.
MSCs were harvested from the patients’ ilium using aspiration, col-
lected in a 30ml syringe and applied at the host bone-allograft junction.
They aimed to retrospectively evaluate the risk of local tumour recur-
rence after surgical tumour resection at a mean of 15.4 years. Using
three control groups, they concluded that the use of MSCs is probably
safe, demonstrating no increase in the risk of local recurrence for all
cancer types [100]. There were some safety concerns about human
ADSC included in fat grafts, however, that were found to increase mi-
gration and metastases in a breast tumour and osteosarcoma models
[74,101].
7.2. In vitro differentiation on scaffolds and re-implantation
Morishita et al. used tissue-engineered osteogenic ceramics to fill
BDs after bone tumour curettage. They isolated BMMSCs that were
osteogenic differentiated to osteoblasts after culture on porous hydro-
xyapatite ceramics [178], shaped based on specific patient needs and
implanted in three patients suffering from a bone tumour. Impressively,
the ceramic consolidated with the bone with no relapse nor loosening at
the 3-month follow up in all patients. The limb was fully loaded at two
and three weeks postoperatively, and no adverse events were reported
in the long-term follow-up.
7.3. Formation of 3D like bone grafts
In a recent study, Dufrane et al. presented a novel technique to treat
a bone nonunion in extreme clinical and pathophysiological conditions
using a human autologous scaffold-free osteogenic 3-dimensional (3D)
graft derived from ADSCs [179]. Autologous ADSCs were in vitro dif-
ferentiated in osteogenic medium, and after 15 to 18 days Deminer-
alized Bone Marrow (DBM) was added to form a 3D scaffold-like graft.
Scaffolds were produced and applied to three patients with bone tu-
mours and three patients with non-unions. The 3D grafts were placed at
the junction between the native host bone and the bone allograft or the
growing prosthesis in cases of tumours. The final osteogenic product
was stable and did not induce acute or long-term donor site morbidity
up to 4 years after transplantation. This research team reported the use
of the same graft in other 11 patients, with bone non-unions [180]. In
total, six patients with bone sarcoma were treated (three osteo-
sarcomas, two Ewing sarcomas and one with chondrosarcoma). Except
for the DBM, no other donor tissue was used, thus overcoming all the
host-to-donor and donor-to-host complications, increasing the safety of
the technique and the chances of graft survival significantly. The 3D-
scaffold was used as a bridge between the native host bone and the
metallic grafts or bone allografts that were used for mechanical stabi-
lization. Abnormal tissue formation was reported in one patient who
had osteosarcoma recurrence, likely related to insufficient surgical
margins after primary tumour resection. Another patient underwent
surgical removal of the graft due to infection. Neither the age of the
patients nor the previous chemotherapy affected the bone healing
process. The patients had a satisfactory quality of life at three years. A
disadvantage of the technique is the time interval between the fat tissue
sample extraction and the application of the 3D-like graft that can be as
long as four months (107±28 days); however, this is a safe period that
minimizes the chance of a subclinical tumour late recurrence.
8. Conclusions and future direction
Novel cellular therapies including Mesenchymal stromal cells,
Dendritic cells, Natural Killer cells, Tumour Infiltrating Lymphocytes,
Chimeric Antigen Receptor T cells, and γδΤ cells constitute a potential
alternative path in bone sarcoma treatment. Using these cell types, we
can achieve greater accumulation of antineoplastic agents in the tu-
mour site while reducing adverse effects [181,182]. Mesenchymal
stromal cells therapies have the potential to alter our therapeutic
strategies, and improve outcomes for patients.
Mesenchymal stromal cells have promise as they can be used as
vectors of antineoplastic agents and for bone defect regeneration after
bone sarcoma resection. However, MSCs may not be safe as a sole
therapy for bone sarcomas because most existing data suggest that they
could accelerate pulmonary metastases after resection of the primary
tumour, promote proliferation of cancer cells at the tumour site and
increase chemoresistance in doxorubicin and cisplatin when interacting
with cancer cells. However, the use of transduced MSCs to express
specific anti-cancer proteins selectively to the tumour site is a pro-
mising therapeutic approach. MSCs expressing TRAIL, OPG, IL-12 or
the CD/5-FC prodrug selectively to tumour site have been studied in-
vitro and in-vivo animal models with promising results. Moreover,
MSCs could be suitable for delivering drugs in osteosarcoma site using
photodynamic techniques.
Bone marrow and adipose tissue were the primary cell source in
most studies using MSCs. However, MSCs isolated from neonatal tissues
appear to have advantages over adult sources; they are usually dis-
carded without use, can be isolated easily and atraumatically with
modern techniques and are associated with fewer adverse effects in
clinical trials. Moreover, MSCs isolated from neonatal tissues have a
lower risk of mutations and present superior proliferative, regenerative
and immunosuppressive potentials over those from adult sources [183].
When it comes to comparison between different neonatal sources, it
seems that foetal MSCs, especially those isolated from the chorionic
membrane and umbilical cord, show a significantly higher expansion
capacity than maternal MSCs [184]. However, the use of foetal MSCs is
challenging as their isolation is possible during the early stages of life
and can harm fetal development.
Recently, there has been a comparison between MSCs derived from
induced pluripotent stem cells and ADMSCs regarding their use for
tissue engineering with both presenting vessel [185] and bone forma-
tion capabilities [186,187], topically tumour progression control [188]
and ease of use for tissue engineering [189,190]. In vivo data for the use
ADMSCs expressing membrane TRAIL is promising for Ewing's sarcoma.
For osteosarcoma, further in vivo study is required. Determining the
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optimal target: effector ratio and degree of physical contact between
the MSCs and cancer cells are areas for future investigation. Also, in
vitro findings may not be found in vivo due to the more heterogeneous
cell populations. A key need is the ability to study microenvironments
using tools which allow for disease modelling and personalized ther-
anostic evaluations. Emerging biofabrication [191] and organ-on-a-
chip approaches seem to offer significant promise in this regard, al-
though a critical challenge is the rate and cost of such models [192].
The development of high-throughput techniques to create and assess
validated micro-tissue models for specific sarcomas would allow for
cellular approaches to be assessed in vitro across heterogeneous po-
pulations and on personalized tissue models.
As no defined protocols exist for treating large bone defects after
tumour resection, the above studies offer some promising results of
different techniques [193]. Technology provides us with the means to
“navigate” the MSCs and transform them into other cell types with
different capabilities promoting healing and playing an antitumor role.
Thus, using tissue engineering technology, we can build a portfolio of
smart biomaterials and have a more personalized therapy applied, po-
tentially with antitumor and osteogenic capabilities. Nowadays, we can
manipulate the implanted grafts pre- or intra-operatively. Two and
three-dimensional co-cultures systems have been widely studied in
order to understand the relationship between cancer and surrounding
cells, follow cancer progression and study different drugs. 3D co-cul-
tures are gaining importance as they can closely mimic the cancer en-
vironment using porous and ECM-like structures that allow a more
biological cell response when compared with the 2D cultures. This will
be reflected not only on fundamental culture properties, such as pro-
liferation or cell morphology but also in protein and gene expression
profiles. These enhanced and more realistic cell properties are ap-
pealing for drug screening assays. Concerning bone sarcomas, these
strategies can mimic sarcoma biological microenvironment, giving
more realistic information about the diseases. Gao et al., thoroughly
reviewed this topic.
Although cellular strategies offer promise, cell behaviour is complex
and in vitro and animal models are not always predictive of human in
vivo response. Thus, better models which allow mechanistic studies
using human cells are required. MSC may have value in creating im-
proved patient derived xenograft (PDX) models of osteosarcoma. The
addition of MSC to a tumor specimen may enhance implantation into an
immunodeficient mouse in a manner superior to that seen with Matrigel
alone. We may not be far from the broad application of mesenchymal
stromal cells as first-line therapy for bone sarcoma, as there have been
made steps to more personalized cell therapy.
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